4 results
Efficacy and safety during 24 treatment weeks.
The main objectives Investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.…
Primary: To demonstrate non-inferiority of RELVAR 100/25 once-daily to SERETIDE 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent asthma,adequately controlled on twice-daily ICS/LABA. Secondary: Adverse…
The primary objective is to investigate whether the use of patient-specific cutting guides for an open wedge high tibial osteotomy (HTO) provide a more accurate correction relative to the preoperative planning compared to the conventional osteotomy…